Talk:Kristy M. Ainslie/Archive 1

Edited page
Edits to include secondary sources

Kristy M. Ainslie is a pharmaceutical science professor at University of North Carolina at Chapel Hill in the Eshelman School of Pharmacy. She is also joint in the UNC School of Medicine Department of Microbiology and Immunology and affiliated faculty in the UNC/NC State joint Biomedical Engineering department. Additionally, she is part of UNC's Biological and Biomedical Sciences Program (BBSP).

Ainslie completed her Bachelors of Science in Chemical engineering from Michigan State University in 1999. After working as a environmental engineer at Malcolm Pirnie, she began graduate school at Penn State as a fellow in the Huck Institutes of the Life Science. In 2003, she completed her Masters of Science in Chemical engineering under John Tarbell, focusing on shear stress modulation of vascular smooth muscle cell contraction. Two years later in 2005, she completed her PhD in Chemical engineering under Micheal Pishko, focusing on protein adhesion and cell responses to nanomaterials. After a brief post doc at the microcantilever start-up Protiveris, she worked with Lloyd Whitman at the United States Naval Research Laboratory. In 2006, she began a post doc at University of San Francisco in the Department of Bioengineering and Therapeutic Sciences under the direction of Tejal Desai. The focus of Ainslie's research at UCSF was on microfabricated oral drug delivery carriers and immune responses to planar nanomaterials.
 * Background==

Ainslie began her career as a tenure track Assistant Professor at Ohio State University in the School of Pharmacy in the Division of Pharmaceutics and Pharmaceutical Chemistry. In 2014, Ainslie moved to the University of North Carolina at Chapel Hill and the UNC Eshelman School of Pharmacy Division of Pharmacoengineering and Molecular Pharmaceutics as an Associate Professor.[

Ainslie has several ares of focus for her lab including immune therapies to treat and prevent infectious diseases.
 * Career==
 * Advancement of acetalated dextran: Establishment of an ethanol producing version of acetalated dextran, in comparison to the methanol producing version first reported by Jean Fréchet. Exploiting the unique degradation rates of acetalated dextran, the Ainslie Lab was the first to show that fine tuning of antigen and adjuvant release can be used to optimize microparticulate vaccines.
 * Antigen specific immune tolerance: One of the first to apply microparticles for autoimmune therapeutic vaccines, using acetalated dextran to suppress disease related inflammation
 * Host-directed therapeutics: First identifying OSU-03012 antiparasitic activity against Leishmania donovani. To improve the delivery of this compound, since it has a narrow therapeutic window, the Ainslie lab encapsulated it in acetalated dextran microparticles and also applied the formulation for Salmonella enterica and Francisella tularensis infection.
 * Electrospray for vaccines: Reported the first use of electrospray for formation of protein based microparticle vaccines made of acetalated dextran. The application of electrospray was then expanded to encapsulate the hydrophillic STING agonist cGAMP.
 * Electrospun acetalated dextran nanofibers: Used for interstitial delivery of chemotherapeutics for glioblastoma.


 * Awards==
 * 2012	OSU Council of Graduate Students James M. Siddens Distinguished Faculty Advising Award
 * 2009	Controlled Release Society Outstanding Oral Drug Delivery Award
 * 2007    Controlled Release Society-Capsugel Post-Doc Award for Innovative Aspects of Oral Drug Delivery & Absorption
 * 2005    Walter R. and Aura Lee Supina Graduate Fellowship in Chemical Engineering
 * 2000	The Pennsylvania State University Life Science Consortium Graduate Fellowship
 * 1999    Commencement Speaker for Michigan State University College of Engineering Graduation Ceremony


 * References==

-- — Preceding unsigned comment added by SithLordSparklePants (talk • contribs) 14:25, 27 July 2018 (UTC)
 * External links==
 * Google Scholar


 * It isn't helpful to post the entire re-written article here, I can't work out what you have changed, added or edited, please post just your specific change with the relevant reference instead. Thank you. Theroadislong (talk) 15:16, 27 July 2018 (UTC)